A Study for the Production of a Personalized Neoantigen Cancer Vaccine



Status:Recruiting
Conditions:Lung Cancer, Prostate Cancer, Colorectal Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/9/2019
Start Date:July 25, 2018
End Date:December 2019
Contact:Andy Ferguson
Email:aferguson@gritstone.com
Phone:857-327-9816

Use our guide to learn which trials are right for you!

An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine in Patients With Advanced Cancer

The purpose of this study is to evaluate the feasibility of manufacturing a personalized
neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating
a vaccine that encodes the predicted neoantigens.

The process of generating a personalized neoantigen cancer vaccine involves multiple steps,
including collection of patient tumor and blood specimens, performing next-generation
sequencing (NGS), predicting the neoantigens to be included in the patient-specific vaccine,
and the manufacture and release of the patient-specific vaccine. Gaining experience in
managing the manufacturing process will provide important insights and experience regarding
this process to be used in operationalizing future clinical trials.

Study participants will not receive any investigational treatment as part of this trial.
Patients for whom vaccine is successfully manufactured may be able to enroll in a separate
investigational treatment study sponsored by Gritstone Oncology, provided that the patient
meets the specified eligibility criteria for that treatment study.

Inclusion Criteria:

- Provide a signed and dated informed consent form prior to initiation of study-specific
procedures

- Patients with the indicated advanced or metastatic solid tumor as follows:

1. NSCLC who have received ≤ 1 cycle of systemic treatment with cytotoxic,
platinum-based chemotherapy (Note: patients with NSCLC who are receiving
pembrolizumab monotherapy as first line systemic monotherapy are eligible)

2. GEA who have received ≤ 1 cycle of systemic treatment with cytotoxic,
platinum-based chemotherapy

3. mUC who have received ≤ 1 cycle of systemic treatment with cytotoxic,
platinum-based chemotherapy

4. CRC-microsatellite stable (MSS) who have received ≤ 1 cycle of second line
systemic therapy including a fluoropyrimidine and oxaliplatin or irinotecan
(Note: patients receiving first-line systemic therapy are eligible)

- 18 years of age or older

- ECOG Performance Status 0 or 1

- Available FFPE tumor specimen for sequencing and neoantigen selection

- Measurable disease according to RECIST v1.1 Have adequate organ function, as measured
by laboratory values (criteria listed in protocol)

Exclusion Criteria:

- Tumors with genetic characteristics as follows:

1. For NSCLC, patients with a known driver genomic alteration in EGFR, ALK, ROS1,
RET, or TRK

2. For CRC or GEA, patients with MSI disease

3. For CRC, patients with a known BRAF mutation or patients with peritoneal
carcinomatosis

Complete inclusion and exclusion criteria are listed in the clinical study protocol.
We found this trial at
5
sites
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials